1887

Abstract

Current practice guidelines recommend that pulmonary blastomycosis be treated with antifungal agents such as amphotericin B and itraconazole. Echinocandins are not recommended because of poor activity against and lack of supporting clinical data. We report a case of chronic pulmonary blastomycosis treated successfully with caspofungin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.036103-0
2011-12-01
2021-03-04
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/12/1875.html?itemId=/content/journal/jmm/10.1099/jmm.0.036103-0&mimeType=html&fmt=ahah

References

  1. Antony S. 2004; Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. Clin Infect Dis 39:879–880 [CrossRef][PubMed]
    [Google Scholar]
  2. Bariola J. R., Perry P., Pappas P. G., Proia L., Shealey W., Wright P. W., Sizemore J. M., Robinson M., Bradsher R. W. Jr 2010; Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 50:797–804 [CrossRef][PubMed]
    [Google Scholar]
  3. Bradsher R. W. 1996; Histoplasmosis and blastomycosis. Clin Infect Dis 22:Suppl. 2S102–S111 [CrossRef][PubMed]
    [Google Scholar]
  4. Bradsher R. W., Bariola J. R. 2011; Blastomycosis. In Essentials of Clinical Mycology, 2nd edn. pp. 337–348 Edited by Kauffman C. A., Pappas P. G., Sobel J. D., Dismukes W. E. New York: Springer;
    [Google Scholar]
  5. Chapman S. W., Dismukes W. E., Proia L. A., Bradsher R. W., Pappas P. G., Threlkeld M. G., Kauffman C. A. 2008; Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 46:1801–1812 [CrossRef][PubMed]
    [Google Scholar]
  6. Chen J., Song X., Yang P., Wang J. 2009; Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. Ann Pharmacother 43:537–541 [CrossRef][PubMed]
    [Google Scholar]
  7. CLSI 2008a; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn. M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute;
  8. CLSI 2008b; Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 3rd edn. M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute;
  9. De Pauw B., Walsh T. J., Donnelly J. P., Stevens D. A., Edwards J. E., Calandra T., Pappas P. G., Maertens J., Lortholary O. et al. other authors 2008; Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821 [CrossRef][PubMed]
    [Google Scholar]
  10. Espinel-Ingroff A. 1998; Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36:2950–2956[PubMed]
    [Google Scholar]
  11. Galgiani J. N., Ampel N. M., Blair J. E., Catanzaro A., Johnson R. H., Stevens D. A., Williams P. L.on behalf of the Infectious Diseases Society of America 2005; Coccidioidomycosis. Clin Infect Dis 41:1217–1223 [CrossRef][PubMed]
    [Google Scholar]
  12. González G. M., Tijerina R., Najvar L. K., Bocanegra R., Luther M., Rinaldi M. G., Graybill J. R. 2001; Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 45:1854–1859 [CrossRef][PubMed]
    [Google Scholar]
  13. Janssen 2011; Product Monograph – Sporanox. Toronto: Janssen Inc;
  14. Kralt D., Light B., Cheang M., MacNair T., Wiebe L., Limerick B., Sarsfield P., Hammond G., MacDonald K. et al. other authors 2009; Clinical characteristics and outcomes in patients with pulmonary blastomycosis. Mycopathologia 167:115–124 [CrossRef][PubMed]
    [Google Scholar]
  15. Nakai T., Uno J., Ikeda F., Tawara S., Nishimura K., Miyaji M. 2003; In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47:1376–1381 [CrossRef][PubMed]
    [Google Scholar]
  16. Pinto A., Chan R. C. 2009; Lack of allergic cross-reactivity between fluconazole and voriconazole. Antimicrob Agents Chemother 53:1715–1716 [CrossRef][PubMed]
    [Google Scholar]
  17. Saccente M., Woods G. L. 2010; Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 23:367–381 [CrossRef][PubMed]
    [Google Scholar]
  18. Sarosi G. A., Davies S. F., Phillips J. R. 1986; Self-limited blastomycosis: a report of 39 cases. Semin Respir Infect 1:40–44[PubMed]
    [Google Scholar]
  19. Sugar A. M., Liu X. P. 1996; In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40:1314–1316[PubMed]
    [Google Scholar]
  20. Sugar A. M., Liu X. P. 2001; Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 45:601–604 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.036103-0
Loading
/content/journal/jmm/10.1099/jmm.0.036103-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error